HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,533-2,544 of 4,505
Drug study icon
CompletedNCT00706654

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in people with Schizophrenia

Official study title

A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 18–60
Countries
United States, France, Belgium, + 11 others
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT00575666

Intranasal Insulin Treatment in people with Schizophrenia

Official study title

Intranasal Insulin Treatment in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

In Worcester
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
University of Massachusetts, Worcester
Drug study icon
CompletedNCT00088075

Investigate Risperidone for Schizophrenia in Adolescents

What is this study about?

This study evaluated the safety and effectiveness of Risperidone for people with schizophrenia.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 13–17
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT01323205

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in people with Schizophrenia

Official study title

First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Innsbruck
SchizophreniaMedication studyAges 18–65
Countries
Belgium, Austria, Bulgaria, + 3 others
Sponsor
Janssen Research & Development, LLC

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.